Cover Image
Market Research Report

Colombia Organ Transplant Immunosuppressant Drugs Market - Industry Trends and Forecast to 2027

Published by Data Bridge Market Research Private Limited Product code 921318
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
Colombia Organ Transplant Immunosuppressant Drugs Market - Industry Trends and Forecast to 2027
Published: December 1, 2019 Content info: 100 Pages
Description

Colombia organ transplant immunosuppressant drugs market is projected to register a steady CAGR in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation

Colombia organ transplant immunosuppressant drugs market by Organ Type (Kidney, Liver, Heart, Lung, Pancreas, Others), Drug Class (Calcineurin Inhibitors, Antimetabolite Immunosuppressants, Steroids, mTOR Inhibitor, Monoclonal Antibody, Others), Drug Type (Generics, Branded), Route of Administration (Oral, Parenteral), End User (Hospitals, Transplant Centers), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Country (Colombia)_Market Trends and Forecast to 2027.

Some of the major factors contributing to the growth of the market are:

  • Rising cases of organ transplantation
  • Government initiatives to promote organ donation

Key Market Players

The key market players for Colombia organ transplant immunosuppressant drugs market are listed below:

  • Pfizer Inc.
  • Astellas Pharma Inc.
  • Sanofi
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dr. Reddy's Laboratories Ltd.
  • Alkem Labs
  • Abbott
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF COLOMBIA ORGAN TRANSPLANT MMUNOSUPPRESSANT DRUGS MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 PRODUCTS LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 PIPELINE ANALYSIS

6 MARKET OVERVIEW

  • 6.1 DRIVERS
    • 6.1.1 RISING CASES OF ORGAN TRANSPLANTATION
    • 6.1.2 GOVERNMENT INITIATIVES TO PROMOTE ORGAN DONATION
    • 6.1.3 INCREASING DEMAND OF KIDNEY TRANSPLANTATION
  • 6.2 RESTRAINTS
    • 6.2.1 STRINGENT REGULATORY PROCEDURES
    • 6.2.2 REDUCTION IN MEDICAL TOURISM FOR ORGAN TRANSPLANTS
    • 6.2.3 HIGH COST OF IMMUNOSUPPRESSANT DRUGS
  • 6.3 OPPORTUNITY
    • 6.3.1 DEVELOPING NEW IMMUNOSUPPRESSION FOR THE NEXT GENERATION OF TRANSPLANT RECIPIENTS

  • 6.4 CHALLENGES
    • 6.4.1 ORGAN REJECTION AND SIDE EFFECTS ASSOCIATED WITH IMMUNOSUPPRESSANT DRUGS
    • 6.4.2 LONG WAITLIST FOR RECIPIENTS FOR ORGAN TRANSPLANT

7 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TYPE

  • 7.1 OVERVIEW
  • 7.2 KIDNEY
  • 7.3 LIVER
  • 7.4 HEART
  • 7.5 MLUNG
  • 7.6 PANCREAS
  • 7.7 OTHERS

8 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS

  • 8.1 OVERVIEW
  • 8.2 CALCINEURIN INHIBITORS
    • 8.2.1 TACROLIMUS
    • 8.2.2 CYCLOSPORINE
  • 8.3 ANTIMETABOLITE IMMUNOSUPPRESSANTS
    • 8.3.1 MYCOPHENOLATE MOFETIL
    • 8.3.2 MYCOPHENOLATE SODIUM
    • 8.3.3 AZATHIOPRINE
  • 8.4 STEROIDS
    • 8.4.1 PREDNISONE
    • 8.4.2 METHYLPREDNISOLONE
  • 8.5 M-TOR INHIBITOR
    • 8.5.1 EVEROLIMUS
    • 8.5.2 SIROLIMUS
  • 8.6 MONOCLONAL ANTIBODY
    • 8.6.1 BASILIXIMAB
    • 8.6.2 MUROMONAB
  • 8.7 OTHERS

9 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG TYPE

  • 9.1 OVERVIEW
  • 9.2 GENERICS
  • 9.3 BRANDED

10 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • 10.1 OVERVIEW
  • 10.2 ORAL
  • 10.3 PARENTERAL

11 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY END USER

  • 11.1 OVERVIEW
  • 11.2 HOSPITALS
  • 11.3 TRANSPLANT CENTERS

12 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 12.1 OVERVIEW
  • 12.2 HOSPITAL PHARMACIES
  • 12.3 RETAIL PHARMACIES
  • 12.4 ONLINE PHARMACIES

13 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, COMPANY LANDSCAPE

  • 13.1 COMPANY SHARE ANALYSIS: COLOMBIA

14 COMPANY PROFILES

  • 14.1 NOVARTIS AG
    • 14.1.1 COMPANY SNAPSHOT
    • 14.1.2 REVENUE ANALYSIS
    • 14.1.3 PRODUCT PORTFOLIO
    • 14.1.4 RECENT DEVELOPMENT
  • 14.2 PFIZER INC.
    • 14.2.1 COMPANY SNAPSHOT
    • 14.2.2 REVENUE ANALYSIS
    • 14.2.3 PRODUCT PORTFOLIO
    • 14.2.4 RECENT DEVELOPMENT
  • 14.3 F. HOFFMANN-LA ROCHE LTD
    • 14.3.1 COMPANY SNAPSHOT
    • 14.3.2 REVENUE ANALYSIS
    • 14.3.3 PRODUCT PORTFOLIO
    • 14.3.4 RECENT DEVELOPMENT
  • 14.4 ASTELLAS PHARMA INC.
    • 14.4.1 COMPANY SNAPSHOT
    • 14.4.2 REVENUE ANALYSIS
    • 14.4.3 PRODUCT PORTFOLIO
    • 14.4.4 RECENT DEVELOPMENT
  • 14.5 ABBOTT
    • 14.5.1 COMPANY SNAPSHOT
    • 14.5.2 REVENUE ANALYSIS
    • 14.5.3 PRODUCT PORTFOLIO
    • 14.5.4 RECENT DEVELOPMENT
  • 14.6 ALKEM LABS
    • 14.6.1 COMPANY SNAPSHOT
    • 14.6.2 REVENUE ANALYSIS
    • 14.6.3 PRODUCT PORTFOLIO
    • 14.6.4 RECENT DEVELOPMENT
  • 14.7 BAYER AG
    • 14.7.1 COMPANY SNAPSHOT
    • 14.7.2 REVENUE ANALYSIS
    • 14.7.3 PRODUCT PORTFOLIO
    • 14.7.4 RECENT DEVELOPMENT
  • 14.8 BRISTOL-MYERS SQUIBB COMPANY
    • 14.8.1 COMPANY SNAPSHOT
    • 14.8.2 REVENUE ANALYSIS
    • 14.8.3 PRODUCT PORTFOLIO
    • 14.8.4 RECENT DEVELOPMENT
  • 14.9 DR. REDDY'S LABORATORIES LTD.
    • 14.9.1 COMPANY SNAPSHOT
    • 14.9.2 REVENUE ANALYSIS
    • 14.9.3 PRODUCT PORTFOLIO
    • 14.9.4 RECENT DEVELOPMENT
  • 14.10 SANOFI
    • 14.10.1 COMPANY SNAPSHOT
    • 14.10.2 REVENUE ANALYSIS
    • 14.10.3 PRODUCT PORTFOLIO
    • 14.10.4 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 ORGAN TRANSPLANTS IN COLOMBIA (1966-2017)
  • TABLE 2 TRANSPLANT PROGRAMS PER CITIES AND ORGAN
  • TABLE 3 PRICE OF IMMUNOSUPPRESSANT DRUGS IN USD
  • TABLE 4 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TYPE, 2018-2027 (ORGAN TRANSPLANT)
  • TABLE 5 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TYPE, 2018-2027 (USD MILLION)
  • TABLE 6 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)
  • TABLE 7 COLOMBIA CALCINEURIN INHIBITORS IN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)
  • TABLE 8 COLOMBIA ANTIMETABOLITE IMMUNOSUPPRESSANTS IN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)
  • TABLE 9 COLOMBIA STEROIDS IN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)
  • TABLE 10 COLOMBIA M-TOR INHIBITOR IN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)
  • TABLE 11 COLOMBIA MONOCLONAL ANTIBODY IN ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION)
  • TABLE 12 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)
  • TABLE 13 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • TABLE 14 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)
  • TABLE 15 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: SEGMENTATION
  • FIGURE 2 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: DATA TRIANGULATION
  • FIGURE 3 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: DROC ANALYSIS
  • FIGURE 4 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: COUNTRY VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 9 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: SEGMENTATION
  • FIGURE 10 RISING CASES OF ORGAN TRANSPLANTATION AND GOVERNMENT INITIATIVES TO PROMOTE ORGAN DONATION IS DRIVING THE COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
  • FIGURE 11 KIDNEY IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET IN 2020 & 2027
  • FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET
  • FIGURE 13 RENAL REPLACEMENT THERAPY IN THE COLOMBIA
  • FIGURE 14 KIDNEY TRANSPLANTATION IN COLOMBIA
  • FIGURE 15 CHORIONIC KIDNEY DISEASES
  • FIGURE 16 TRANSPLANTS PERFORMED IN BOTH, COLUMBIAN AND NON-COLUMBIAN CITIZENS (2005-2017)
  • FIGURE 17 DONOR PER MILLION IN COLOMBIA (2008-2017)
  • FIGURE 18 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET DOMINATED BY KIDNEY (2019)
  • FIGURE 19 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY ORGAN TYPE, 2018-2027 (USD MILLION)
  • FIGURE 20 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY ORGAN TYPE, CAGR (2020-2027)
  • FIGURE 21 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY ORGAN TYPE, LIFELINE CURVE
  • FIGURE 22 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET DOMINATED BY CALCINEURIN INHIBITORS (2019)
  • FIGURE 23 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY DRUG CLASS, 2018-2027 (USD MILLION)
  • FIGURE 24 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY DRUG CLASS, CAGR (2020-2027)
  • FIGURE 25 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE
  • FIGURE 26 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET DOMINATED BY GENERICS (2019)
  • FIGURE 27 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY DRUG TYPE, 2018-2027 (USD MILLION)
  • FIGURE 28 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY DRUG TYPE, CAGR (2020-2027)
  • FIGURE 29 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE
  • FIGURE 30 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET DOMINATED BY ORAL (2019)
  • FIGURE 31 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
  • FIGURE 32 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
  • FIGURE 33 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
  • FIGURE 34 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET DOMINATED BY HOSPITALS (2019)
  • FIGURE 35 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY END USER, 2018-2027 (USD MILLION)
  • FIGURE 36 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY END USER, CAGR (2020-2027)
  • FIGURE 37 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 38 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET DOMINATED BY HOSPITAL PHARMACIES (2019)
  • FIGURE 39 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY DISTRIBUTION CHANNEL: 2018-2027 (USD MILLION)
  • FIGURE 40 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
  • FIGURE 41 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
  • FIGURE 42 COLOMBIA ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS MARKET: COMPANY SHARE 2019 (%)
Back to Top